Why the study?
Does dabigatran etexilate prevent stroke and systemic embolism in patients with atrial fibrillation compared to vitamin K antagonists?
Does dabigatran etexilate prevent stroke and systemic embolism in patients with atrial fibrillation compared to vitamin K antagonists?
This document outlines the NICE guidance for using dabigatran etexilate as an alternative to warfarin for stroke prevention in patients with atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
NICE endorsement of dabigatran for atrial fibrillation stroke prevention may shift UK practice from warfarin; extends pivotal trial data into guidelines.
Ahmad et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: